Peter Greenleaf Sells 195,593 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP CEO Peter Greenleaf sold 195,593 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $1,564,744.00. Following the completion of the transaction, the chief executive officer now owns 1,953,892 shares in the company, valued at approximately $15,631,136. The trade was a 9.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Aurinia Pharmaceuticals Stock Performance

Shares of NASDAQ:AUPH traded down $0.04 during trading on Friday, hitting $8.15. 1,152,887 shares of the company were exchanged, compared to its average volume of 1,481,486. The company has a market cap of $1.12 billion, a PE ratio of -54.33 and a beta of 1.26. The stock has a 50 day moving average of $8.08 and a 200 day moving average of $7.88. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.71 and a 52-week high of $10.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 19th.

Remove Ads

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Tang Capital Management LLC raised its position in shares of Aurinia Pharmaceuticals by 16.6% in the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company's stock worth $75,697,000 after buying an additional 1,200,000 shares in the last quarter. State Street Corp raised its position in shares of Aurinia Pharmaceuticals by 2.3% in the third quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company's stock worth $21,587,000 after buying an additional 64,949 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Aurinia Pharmaceuticals by 6.9% in the fourth quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company's stock worth $15,535,000 after buying an additional 112,113 shares in the last quarter. Nuveen Asset Management LLC increased its stake in Aurinia Pharmaceuticals by 10.2% in the fourth quarter. Nuveen Asset Management LLC now owns 1,492,301 shares of the biotechnology company's stock valued at $13,401,000 after acquiring an additional 138,054 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in Aurinia Pharmaceuticals in the fourth quarter valued at $9,662,000. Hedge funds and other institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.